Phaseline

Targets › LILRA6

LILRA6 (Leukocyte immunoglobulin-like receptor subfamily A member 6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

May act as receptor for class I MHC antigens. (UniProt, Q6PI73)

Open in Phaseline: the race on LILRA6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Second Affiliated Hospital, Zhejiang University, School of MedicineAnti-LILRA6 CAR-T cells
anti-LILRA6 chimeric antigen receptor T cell therapy
LILRA6Phase 1Refractory Acute Myeloid LeukemiaOct 2027

Conditions

Refractory Acute Myeloid Leukemia (1)

Modalities

other (1)

Companies

Second Affiliated Hospital, Zhejiang University, School of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.